David A. Tice BS, PhD

Dr. David Tice has over 17 years of biopharmaceutical research experience. He spent the last 14 years at MedImmune, a subsidiary of Astrazeneca, where he currently heads the Antibody Drug Conjugate research group. Throughout his tenure at MedImmune, David has led several preclinical/clinical phase programs employing various therapeutic approaches including monoclonal antibodies, immunoconjugates, peptide mimetics, and RNAi targeting various molecules important in the development of cancer. Prior to this experience David worked at Genentech, Inc. where he focused on genomics-based target discovery and monoclonal antibody targeting in cancer. David began his training at the University of Virginia where he received his PhD.